ImmunoCellular Therapeutics, Ltd. - FORM 10-K - EX-23.1 - CONSENT OF MARCUM LLP. - March 21, 2012

Attached files

file filename
10-K - FORM 10-K - ImmunoCellular Therapeutics, Ltd.d283327d10k.htm
EX-10.51 - EXCLUSIVE LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1051.htm
EX-23.2 - CONSENT OF STONEFIELD JOSEPHSON, INC. - ImmunoCellular Therapeutics, Ltd.d283327dex232.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex312.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex311.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 - ImmunoCellular Therapeutics, Ltd.d283327dex321.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 - ImmunoCellular Therapeutics, Ltd.d283327dex322.htm
EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd.Financial_Report.xls
EX-10.50 - PATENT LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1050.htm

Exhibit 23.1

Independent Registered Public Accounting Firm’s Consent

We consent to the incorporation by reference in the Registration Statements of ImmunoCellular Therapeutics, Ltd. on Form S-8 (File Nos. 333171652, 333-155199, 333-151968 and 333-147278) of our report dated March 21, 2012 with respect to our audits of the financial statements of ImmunoCellular Therapeutics, Ltd. as of December 31, 2011 and 2010 and for each of the two years ended December 31, 2011 and the period from February 25, 2004 (inception) to December 31, 2011, which report is included in this Annual Report on Form 10-K of ImmunoCellular Therapeutics, Ltd. for the year ended December 31, 2011.

/s/ Marcum LLP

Los Angeles, California

March 21, 2012

ImmunoCellular Therapeutics, Ltd. Reports